News

Innovation and new products

Sitagliptin promotes macrophage-to-feces RCT in obese insulin resistant CETP-apoB100 transgenic mice.

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveil the results of a new study that supports the potential of dipeptidyl peptidase-4 (DPP-4) inhibitors to promote Reverse Cholesterol Transport (RCT) through reduced intestinal cholesterol absorption.

CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveils the results of a new study that supports the potential of CETP inhibitors to prevent cardiovascular risk like dyslipidemia, a major characteristic of type 2 diabetic patients.

A new study demonstrates that the CETP inhibitor anacetrapib promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

Using independent approaches to assess cholesterol metabolism (macrophage-to-feces reverse cholesterol transport, HDL-cholesteryl esters kinetics and measurement of bulk cholesterol and bile acids in feces), this study supports the development of the CETP inhibitor anacetrapib as a novel lipid therapy for the treatment of dyslipidemia and atherosclerosis.

New non alcoholic steatohepatitis (NASH) model

Physiogenex unveils a new nutritional animal model that enables the study of the non-alcoholic fatty liver disease (NAFLD).

Reverse Cholesterol Transport

A new study demonstrates that diet-induced dyslipidemia per se impairs macrophage-to-feces reverse cholesterol transport in a hamster model.

Reverse Cholesterol Transport experiments

Physiogenex offers the state-of-the-art technique to demonstrate that your compound promotes reverse cholesterol transport and has therefore the potential to prevent atherosclerosis and cardiovascular diseases.

An original hamster nutritional model dedicated to mimic human hypercholesterolemia and specifically designed to cholesterol and lipoproteins studies.

Physiogenex sponsors and presents scientific results at the DEUEL conference on Lipids, March 6 – 9, 2012, CA, USA.

Physiogenex is proud to partner this high-quality conference dealing with many aspects of lipid/lipoprotein metabolism.

Physiogenex to present at International Symposium on Atherosclerosis, 30 March - 1 April 2012, Australia.

Dr François Briand will present a poster on “Up-regulation of reverse cholesterol transport requires reduction of apoliprotein-E rich HDL levels in hyperlipidemic hamsters treated with CETP inhibitor torcetrapib.”

Physiogenex obtains the French CIR accreditation

Physiogenex to present scientific results at the American Heart Association annual congress, November 12-16, 2011 in Orlando, Florida, USA.

Dr François Briand, Head of Diabetic Dyslipidemia is pleased to present Physiogenex’s latest developments in the field of dyslipidemia. He will present in an oral presentation "An alternative method to measure in vivo Reverse Cholesterol Transport (RCT) in hyperlipidemic hamsters."

Physiogenex to attend NYAS conference on animal models, September 15-16, 2011 in New York, USA

Betagenex and Physiogenex will attend the 2011 American Diabetes Association annual meeting.

Vincent Poitout, DVM, PhD (Betagenex founder, Chair of the Board of Directors) and Thierry Sulpice, PhD (Physiogenex, CSO and Managing Director and Bêtagenex founder, CEO and CSO) will attend the 2011 ADA meeting.

Physiogenex to present scientific results at the American Diabetes Association annual congress, June 24th-28th 2011 in San Diego, California, USA.

Scientific results regarding a new study “DPP−4 inhibitor Sitagliptin improves reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP−apoB100 transgenic mice” will be presented by Dr François Briand, Head of Diabetic Dyslipidemia at Physiogenex.

Physiogenex to present at KinMet meeting April 27th 2011 in Chicago, Illinois, USA.

Dr François Briand presents "An alternative method to measure in vivo macrophage-to-feces reverse cholesterol transport in hamsters".

Physiogenex to present at Prediabetes & Metabolic Syndrom April 6th-9th 2011 in Madrid, Spain.

Dr Bénédicte Marcassus, Head of Diabetes/Obesity at Physiogenex will present a poster showing the effects of antidiabetic drugs on renal damages in insulin resistant hypertensive Dahl rats fed with a high salt/sucrose diet.

Physiogenex is sponsoring the DEUEL conference on March 1st-4th 2011 in Napa, CA, USA.

Physiogenex is partnering the best meeting of the year for industry-academic interactions, around many aspects of lipid/lipoprotein metabolism.

AHA Scientific session 2010 in Chicago, Illinois Nov 13–17 2010

Physiogenex will be present at AHA Scientific session 2010 in Chicago, Illinois Nov 13–17 2010.

Physiogenex is sponsoring the PCSK9 conference on March 11th-13th 2010 in Nantes, France

Physiogenex is partnering the first international conference on PCSK9, a circulating protein that modulates LDL-cholesterol levels by degrading the LDL-receptor. Development of PCSK9 inhibitors represents a promising target, a proof of interest already validated in humans.

Physiogenex to present at the KinMet 2010 & ATVB 2010 annual conference in San Francisco, April 7th-10th, 2010

Physiogenex will present the effects of CETP inhibitor torcetrapib on macrophage-to-feces reverse cholesterol transport in the obese insulin resistant CETP-apoB100 transgenic mice.

Physiogenex to present at the American Heart Association (AHA) scientific sessions 2009, November 14th-18th; Orlando, FL, USA

Physiogenex is proud to present the effects of Liver-X -Receptor activation on macrophage-to-feces reverse cholesterol transport in dyslipidemic hamsters in vivo.

Print Top